Carl G. Figdor

Regulation of LFA-1 Expression by CD34 Positive Cells and Inducible Growth Factor Production by Stroma Enable Formation of Bone Marrow Compartments; Subject Heading.

Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1.

The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells.

C-type lectin receptors on dendritic cells and Langerhans cells.

Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1.

Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes.

The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion.

Phenotypical and functional characterization of clinical grade dendritic cells.

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

Expression of the dendritic cell-associated C-type lectin DC-SIGN by inflammatory matrix metalloproteinase-producing macrophages in rheumatoid arthritis synovium and interaction with intercellular adhesion molecule 3-positive T cells.

Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.

The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells.

The heme-heme oxygenase system: a molecular switch in wound healing.

Different faces of the heme-heme oxygenase system in inflammation.

Analysis of dendritic cell trafficking using EGFP-transgenic mice.

Ceramic hydroxyapatite coating on titanium implants drives selective bone marrow stromal cell adhesion.

An automated multi well cell track system to study leukocyte migration.

Dual function of C-type lectin-like receptors in the immune system.

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells.

Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells.

Dendritic cell immunotherapy: mapping the way.

Differentiating stem cells mask their origins.

Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKCalpha independently of Rho-like GTPases.

In situ tumor ablation creates an antigen source for the generation of antitumor immunity.

Phenotypical and functional characterization of clinical-grade dendritic cells.

The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum.

Novel monoclonal antibodies detect elevated levels of the chemokine CCL18/DC-CK1 in serum and body fluids in pathological conditions.

How C-type lectins detect pathogens.

Migration of dendritic cell based cancer vaccines: in vivo veritas?

"Sweet talk": closing in on C type lectin signaling.

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints.

Levels of complexity in pathogen recognition by C-type lectins.

Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.

Dendritic cells: tools and targets for antitumor vaccination.

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells.

TRPM7, a novel regulator of actomyosin contractility and cell adhesion.

Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination.

Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake.

A critical role for prostaglandin E2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation.

Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.

Organization of the integrin LFA-1 in nanoclusters regulates its activity.

C-type lectins on dendritic cells and their interaction with pathogen-derived and endogenous glycoconjugates.

Targeting antigens to dendritic cells in vivo.

Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR.

Relevance of DC-SIGN in DC-induced T cell proliferation.

Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines.

Binding of the adhesion and pathogen receptor DC-SIGN by monocytes is regulated by the density of Lewis X molecules.

Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production.

Myosin II and mechanotransduction: a balancing act.

Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells.

Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients.

Nanoscale organization of the pathogen receptor DC-SIGN mapped by single-molecule high-resolution fluorescence microscopy.

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model.

Distinct kinetic and mechanical properties govern ALCAM-mediated interactions as shown by single-molecule force spectroscopy.

Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

Monocyte cell surface glycosaminoglycans positively modulate IL-4-induced differentiation toward dendritic cells.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

PGE2-mediated podosome loss in dendritic cells is dependent on actomyosin contraction downstream of the RhoA-Rho-kinase axis.

Massive autophosphorylation of the Ser/Thr-rich domain controls protein kinase activity of TRPM6 and TRPM7.

Interaction of acute lymphopblastic leukemia cells with C-type lectins DC-SIGN and L-SIGN.

Human and murine model cell lines for dendritic cell biology evaluated.

Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients.

TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation.

Selective cancer-germline gene expression in pediatric brain tumors.

Dendritic cell interaction with Candida albicans critically depends on N-linked mannan.

No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation.

Maximizing dendritic cell migration in cancer immunotherapy.

In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.

The alpha-kinases TRPM6 and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC.

Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II.

Mesenchymal stromal cells: tissue engineers and immune response modulators.

Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.

DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production.

In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds.

The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity.

Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.

Dynamic re-organization of individual adhesion nanoclusters in living cells by ligand-patterned surfaces.

The C-type lectin DC-SIGN internalizes soluble antigens and HIV-1 virions via a clathrin-dependent mechanism.

Functional differences between mesenchymal stem cell populations are reflected by their transcriptome.

Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion.

The role of tetraspanins in the pathogenesis of infectious diseases.

Mesenchymal stem cells respond to TNF but do not produce TNF.

Cord blood mesenchymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin-12 production by mature dendritic cells.

Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Fungal pattern-recognition receptors and tetraspanins: partners on antigen-presenting cells.

TLR4-mediated podosome loss discriminates gram-negative from gram-positive bacteria in their capacity to induce dendritic cell migration and maturation.

Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level.

Ovarian cancer creates a suppressive microenvironment to escape immune elimination.

Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche.

Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.

Dendritic cell subsets digested: RNA sensing makes the difference!

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.

Molecular friction as a tool to identify functionalized alkanethiols.

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology.

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.

(19)F MRI for quantitative in vivo cell tracking.

Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging.

Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.

The lymphoid chemokine CCL21 triggers LFA-1 adhesive properties on human dendritic cells.

A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1.

Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses.

Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.

Eradicating cancer cells: struggle with a chameleon.

Multimodal imaging of nanovaccine carriers targeted to human dendritic cells.

DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.

Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.

Infection of dendritic cells with herpes simplex virus type 1 induces rapid degradation of CYTIP, thereby modulating adhesion and migration.

Antigen localization controls T cell-mediated tumor immunity.

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation.

Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor.

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.

Interlaboratory round robin on cantilever calibration for AFM force spectroscopy.

Unraveling the human dendritic cell phagosome proteome by organellar enrichment ranking.

The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.

Geometry sensing by dendritic cells dictates spatial organization and PGE(2)-induced dissolution of podosomes.

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

Harnessing human plasmacytoid dendritic cells as professional APCs.

Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.

Lateral mobility of individual integrin nanoclusters orchestrates the onset for leukocyte adhesion.

Targeting nanoparticles to dendritic cells for immunotherapy.

Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.

The modular nature of dendritic cell responses to commensal and pathogenic fungi.

Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.

Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [(18)F]FLT PET imaging.

Labeling cells for in vivo tracking using (19)F MRI.

Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.

Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.

The neck region of the C-type lectin DC-SIGN regulates its surface spatiotemporal organization and virus-binding capacity on antigen-presenting cells.

ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9.

In vivo imaging of therapy-induced anti-cancer immune responses in humans.

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

In vivo tracking techniques for cellular regeneration, replacement, and redirection.

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

Automated podosome identification and characterization in fluorescence microscopy images.

Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.

Targeting dendritic cells--why bother?

The nature of activatory and tolerogenic dendritic cell-derived signal II.

Dendritic cell-based nanovaccines for cancer immunotherapy.

Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients.

Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force.

Naturally circulating dendritic cells to vaccinate cancer patients.

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination.

Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion.

Aiming to immune elimination of ovarian cancer stem cells.

Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics.

Tumoricidal activity of human dendritic cells.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin S activity localization.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Semaphorin 7A Promotes Chemokine-Driven Dendritic Cell Migration.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Tetraspanin CD37 protects against the development of B cell lymphoma.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Proteome Based Construction of the Lymphocyte Function-Associated Antigen 1 (LFA-1) Interactome in Human Dendritic Cells.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Long-lasting multifunctional CD8 T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses.

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.

Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.

Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function.

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

N-glycan mediated adhesion strengthening during pathogen-receptor binding revealed by cell-cell force spectroscopy.

Migrating into the Tumor: a Roadmap for T Cells.

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Dendritic cells in cancer immunotherapy.

A comparative assessment of continuous production techniques to generate sub-micron size PLGA particles.

C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37.

Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery.

Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity.

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells.

Synthetic Semiflexible and Bioactive Brushes.

Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.

Imaging of T-cells and their responses during anti-cancer immunotherapy.

Microfluidics-Assisted Size Tuning and Biological Evaluation of PLGA Particles.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.

Intracellular Galectin-9 Controls Dendritic Cell Function by Maintaining Plasma Membrane Rigidity.

Cross-talk between iNKT cells and CD8 T cells in the spleen requires the IL-4/CCL17 axis for the generation of short-lived effector cells.

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.

Multicore Liquid Perfluorocarbon-Loaded Multimodal Nanoparticles for Stable Ultrasound and F MRI Applied to In Vivo Cell Tracking.

The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.

Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels.

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer.

Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses.

Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering.

Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.

Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion.

Three distinct tolerogenic CD14 myeloid cell types to actively manage autoimmune disease: Opportunities and challenges.

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.

PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.

Characterization of Intrinsically Radiolabeled Poly(lactic--glycolic acid) Nanoparticles for ex Vivo Autologous Cell Labeling and in Vivo Tracking.

Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery.

Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity.

In Vivo PET Imaging of Monocytes Labeled with [Zr]Zr-PLGA-NH Nanoparticles in Tumor and Infection Models.

Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots.

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.

Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents.

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.

Design of triphasic poly(lactic--glycolic acid) nanoparticles containing a perfluorocarbon phase for biomedical applications.

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.

Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris.

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.